Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest

[1]  John Lahoud,et al.  Perilesional Biopsies Increase Detection of Significant Prostate Cancer in Men with PI-RADS 4/5 Lesions: Validation of the PI-RADS Steering Committee Recommendation. , 2021, European urology.

[2]  A. Rosenkrantz,et al.  Application of the PRECISION Trial Biopsy Strategy to a Contemporary MRI-Targeted Biopsy Cohort: How Many Clinically Significant Prostate Cancers are Missed? , 2020, The Journal of urology.

[3]  P. Carroll,et al.  Update of the AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. , 2020, The Journal of urology.

[4]  I. Burger,et al.  Multimodality Imaging of Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[5]  F. Fraggetta,et al.  Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer , 2019, In Vivo.

[6]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[7]  H. Merisaari,et al.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial) , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Beer,et al.  Follow-up MR imaging of PI-RADS 3 and PI-RADS 4 prostate lesions. , 2017, Clinical imaging.

[9]  Elton Llukani,et al.  The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. , 2017, Urology.

[10]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[11]  M. Bock,et al.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology , 2017, Theranostics.

[12]  M. Schwaiger,et al.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. , 2016, European urology.

[13]  T. Holland-Letz,et al.  Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Fang-Ming Deng,et al.  Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. , 2016, European urology.

[15]  H. Fujimoto,et al.  Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial. , 2016, Japanese journal of clinical oncology.

[16]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[17]  Elton Llukani,et al.  Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy. , 2015, The Journal of urology.

[18]  Ruth Etzioni,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.

[19]  P. Choyke,et al.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. , 2014, Radiology.

[20]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[21]  F DuBois Bowman,et al.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.